|
【结 构 式】 
|
【药物名称】 【化学名称】N1-[2-(Adenin-9-yl)ethyl]-N1'-[3-(6-chloro-2-methoxyacridin-9-ylamino)propyl]propane-1,3-diguanidine 【CA登记号】252899-51-7 【 分 子 式 】C29H36ClN13O 【 分 子 量 】618.14977 |
【开发单位】INSERM (Originator) 【药理作用】Antineoplastic Enhancing Agents, Modulators of the Therapeutic Activity of Antineoplastic Agents, ONCOLYTIC DRUGS |
合成路线1
The known acridine-purine hybrid molecule (I) was converted into the Boc-protected bisguanidine derivative (III) by reaction with bis(tert-butoxycarbonyl)thiourea (II) in the presence of HgCl2 and Et3N. Subsequent acidic cleavage of the Boc groups gave the title compound.
| 【1】 Belmont, P.; et al.; Abasic site recognition in DNA as a new strategy to potentiate the action of anticancer alkylating drugs?. J Med Chem 1999, 42, 25, 5153. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 40720 | N(1)-[2-(6-amino-9H-purin-9-yl)ethyl]-N(3)-[3-[(6-chloro-2-methoxy-9-acridinyl)amino]propyl]-1,3-propanediamine; N-[2-(6-amino-9H-purin-9-yl)ethyl]-N-[3-([3-[(6-chloro-2-methoxy-9-acridinyl)amino]propyl]amino)propyl]amine | C27H32ClN9O | 详情 | 详情 | |
| (II) | 21843 | tert-butyl [(tert-butoxycarbonyl)amino]carbothioylcarbamate | 145013-05-4 | C11H20N2O4S | 详情 | 详情 |
| (III) | 40721 | tert-butyl (E,7E)-2-[2-(6-amino-9H-purin-9-yl)ethyl]-1,7-bis[(tert-butoxycarbonyl)amino]-6-[3-[(6-chloro-2-methoxy-9-acridinyl)amino]propyl]-11,11-dimethyl-9-oxo-10-oxa-2,6,8-triaza-7-dodecen-1-ylidenecarbamate | C49H68ClN13O9 | 详情 | 详情 |
Extended Information